GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » Debt-to-Asset

Perseus Proteomics (TSE:4882) Debt-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics Debt-to-Asset?

Perseus Proteomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.00 Mil. Perseus Proteomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.00 Mil. Perseus Proteomics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was 円1,796.66 Mil. Perseus Proteomics's debt to asset for the quarter that ended in Dec. 2023 was 0.00.


Perseus Proteomics Debt-to-Asset Historical Data

The historical data trend for Perseus Proteomics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perseus Proteomics Debt-to-Asset Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-Asset
Get a 7-Day Free Trial - - - - -

Perseus Proteomics Quarterly Data
Mar18 Mar19 Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Perseus Proteomics's Debt-to-Asset

For the Drug Manufacturers - General subindustry, Perseus Proteomics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perseus Proteomics's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Perseus Proteomics's Debt-to-Asset falls into.



Perseus Proteomics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Perseus Proteomics's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Perseus Proteomics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perseus Proteomics  (TSE:4882) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Perseus Proteomics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Perseus Proteomics (TSE:4882) Business Description

Traded in Other Exchanges
N/A
Address
4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines